secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liquidia Corp (LQDA)
CIK:        0001819576
Form:       8-K
Filed at:   2024-03-13T23:59:59+00:00
Accession:  0001104659-24-033684
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liquidia FY2023 net loss $78.5M ($1.21/sh); patent victory clears path for YUTREPIA launch
--------------------------------------------------------------------------------

- Net loss $78.5M ($1.21/sh) vs $41.0M ($0.67/sh) in FY2022; R&D spend rose 122% to $43.2M.
- Cash $83.7M at Dec 31, 2023; raised $100M in Jan 2024 via equity placement and debt amendment.
- Federal Circuit denied United Therapeutics' rehearing request, upholding invalidity of '793 Patent; injunction removal awaited.
- YUTREPIA ready for launch in PAH and PH-ILD after Tyvaso exclusivity expires March 31, 2024 and injunction lifted.
- L606 Phase 3 PH-ILD study planned by end-2024; ASCENT enrollment (60 patients) ongoing with interim data expected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819576/000110465924033684/0001104659-24-033684-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819576/000110465924033684/tm248678d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-033684

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer